Examination of sinus cavity tumor provides potential roadmap for rare cancer treatments
Knowing how tumors evolve can lead to new treatments that could help prevent cancer from recurring, according to a study published today by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.
TGen researchers tracked several years of tumor evolution in a 47-year-old male patient with maxillary sinus carcinoma (MSC), a rare cancer of the sinus cavities beneath the cheeks that often requires surgical removal that is disfiguring. Fewer than half of MSC patients live more than 5 years after diagnosis.
“The ability to characterize clonal evolution of this rare cancer and identify its Achilles’ heel can significantly impact treatment, leading to more personalized medicine,” according to the study published today in the journal PLOS ONE.
- Published in Cancers